

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>5AM Ventures V, L.P.</u> _____ (Last) (First) (Middle) <u>501 2ND STREET, SUITE 350</u> _____ (Street) <u>SAN FRANCISCO CA 94107</u> _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>10/28/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>Entrada Therapeutics, Inc. [TRDA]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	331,155	I	See Footnote ⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series Seed Preferred Stock	(2)	(2)	Common Stock	318,616	(2)	I	See Footnote ⁽¹⁾
Series A Preferred Stock	(2)	(2)	Common Stock	2,371,739	(2)	I	See Footnote ⁽¹⁾
Series A Preferred Stock	(2)	(2)	Common Stock	564,217	(2)	I	See Footnote ⁽³⁾
Series B Preferred Stock	(2)	(2)	Common Stock	254,512	(2)	I	See Footnote ⁽¹⁾
Series B Preferred Stock	(2)	(2)	Common Stock	318,140	(2)	I	See Footnote ⁽³⁾

1. Name and Address of Reporting Person* <u>5AM Ventures V, L.P.</u> _____ (Last) (First) (Middle) <u>501 2ND STREET, SUITE 350</u> _____ (Street) <u>SAN FRANCISCO CA 94107</u> _____ (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>5AM Partners V, LLC</u> _____ (Last) (First) (Middle) <u>501 2ND STREET, SUITE 350</u> _____ (Street)

SAN CA 94107
FRANCISCO

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[5AM Opportunities I, L.P.](#)

(Last) (First) (Middle)

501 2ND STREET, SUITE 350

(Street)

SAN CA 94107
FRANCISCO

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[5AM Opportunities I \(GP\), LLC](#)

(Last) (First) (Middle)

501 2ND STREET, SUITE 350

(Street)

SAN CA 94107
FRANCISCO

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ROCKLAGE SCOTT M](#)

(Last) (First) (Middle)

501 2ND STREET, SUITE 350

(Street)

SAN CA 94107
FRANCISCO

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Schwab Andrew J.](#)

(Last) (First) (Middle)

501 2ND STREET, SUITE 350

(Street)

SAN CA 94107
FRANCISCO

(City) (State) (Zip)

Explanation of Responses:

1. Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

2. Each share of Series Seed Preferred Stock is convertible into common stock on a 1-for-7.235890014 basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. Each share of Series A Preferred Stock is convertible into Common Stock on a 1-for-7.235890014 basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock is convertible into Common Stock on a 1-for-7.235890014 basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock have no expiration date.

3. Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

